Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 5 spellings of its name, each linked to the record. See the Daiichi Sankyo group view.
As of Nov 15, 2026, FDA's public records list Daiichi Sankyo and its 6 subsidiaries with 119 drug applications, 31 drug recalls, 5 510(k) clearances, 2 complete response letters and 1 OPDP letter. The most recent is an OPDP letter dated Nov 24, 2025: Untitled letter: TURALIO.
Group recordsLabelled by a language model (which subsidiaries belong to the group) from the firm's FDA names. It is not an FDA field.: 158, 7 entities
Drug applications: 119
Drug recalls: 31
510(k) clearances: 5
Complete response letters: 2
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date, Daiichi Sankyo and its 6 subsidiaries
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
72017Records7
320182018Records3vs 2017−4
52019Records5vs 2018+2
220202020Records2vs 2019−3
02021Records0vs 2020−2
420222022Records4vs 2021+4
42023Records4vs 2022+0
920242024Records9vs 2023+5
42025Records4vs 2024−5
1420262026 to dateRecords14
Latest Records
Newest first across sources; each opens the record
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built